A randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer

A. Lipton, H. A. Harvey, R. J. Santen, A. Boucher, D. White, A. Bernath, R. Dixon, G. Richards, A. Shafik

Research output: Contribution to journalArticle

28 Scopus citations


The authors compared antiestrogen therapy (tamoxifen) with an estrogen suppression regimen (aminoglutethimide‐hydrocortisone) in postmenopausal women with metastatic breast carcinoma. Ten of 24 patients (41.5%) who received Tamoxifen experienced an objective tumor regression (three complete, seven partial remissions), whereas ten of 21 women (47.5%) receiving Aminoglutethimide responded (zero complete, ten partial remissions). The median duration of response was similar, 13 months for tamoxifen versus ten months for aminoglutethimide. The site of tumor involvement appears to be important in choosing between these hormonal treatments. Aminoglutethimide appears to offer a greater chance of response in patients with bone involvement.

Original languageEnglish (US)
Pages (from-to)2265-2268
Number of pages4
Issue number11
Publication statusPublished - Dec 1 1982


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this